oxbryta
pfizer europe ma eeig - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
combocoldrex 500 mg/200 mg/10 mg prašek za peroralno raztopino
gvaifenezin; paracetamol; fenilefrinijev klorid - prašek za peroralno raztopino - gvaifenezin 200 mg / 1 vrečica paracetamol500 mg / 1 vrečica fenilefrinijev klorid10 mg / 1 vrečica; paracetamol 500 mg / 1 vrečica fenilefrinijev klorid10 mg / 1 vrečica; fenilefrinijev klorid 10 mg / 1 vrečica - paracetamol, kombinacije brez psiholeptikov